Prevention of meningococcal disease

Area of Science:

• Public Health
• Infectious Diseases
• Vaccinology

Background:

• Neisseria meningitidis causes invasive disease with significant mortality and morbidity, despite antibiotic treatments.
• While most cases are sporadic, meningococcal disease outbreaks necessitate vaccination strategies.
• Serogroup B is prevalent in infants, but serogroups C, Y, and W-135 disproportionately affect adolescents and young adults, who are targeted by new vaccines.

Purpose of the Study:

• To review the epidemiology of invasive meningococcal disease (IMD) in the United States.
• To highlight the approval and recommendations for a new tetravalent meningococcal conjugate vaccine (MenACWY-TT).
• To discuss the vaccine's potential impact on disease prevention in high-risk populations.

Main Methods:

• Review of epidemiological data on Neisseria meningitidis incidence and serogroup distribution in the US.
• Analysis of the characteristics and recommendations for the newly approved tetravalent meningococcal conjugate vaccine (MenACWY-TT).
• Examination of Advisory Committee on Immunization Practices (ACIP) recommendations for vaccine administration.

Main Results:

• Adolescents and young adults (15-24 years) exhibit higher IMD incidence and fatality rates.
• Serogroups C, Y, and W-135 cause 70-80% of US infections in this age group, making them vaccine-preventable.
• A new T-cell-dependent tetravalent meningococcal conjugate vaccine (MenACWY-TT) has been approved, inducing bactericidal antibodies and immunologic memory.

Conclusions:

• The MenACWY-TT vaccine offers a promising strategy for preventing IMD, particularly in adolescents and young adults.
• ACIP recommends routine vaccination for 11-12 year olds, high school entrants, and college freshmen.
• The vaccine is also recommended for specific high-risk groups aged 11-55, potentially reducing disease burden and sequelae.